The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Safety, pharmacokinetics, and pharmacodynamics results from a phase I trial of BAY 86-9766 (RDEA119), a MEK inhibitor, in patients with advanced cancer.
L. Gore
No relevant relationships to disclose
K. Lewis
No relevant relationships to disclose
D. D. Von Hoff
Research Funding - Ardea Biosciences
G. J. Weiss
No relevant relationships to disclose
R. K. Ramanathan
No relevant relationships to disclose
A. A. Adjei
Research Funding - Ardea Biosciences
G. K. Dy
No relevant relationships to disclose
W. W. Ma
No relevant relationships to disclose
N. J. Clendeninn
Consultant or Advisory Role - Ardea Biosciences
Stock Ownership - Ardea Biosciences
D. P. Leffingwell
Consultant or Advisory Role - Ardea Biosciences
B. Sheedy
Stock Ownership - Ardea Biosciences
C. Iverson
Employment or Leadership Position - Ardea Biosciences
Stock Ownership - Ardea Biosciences
J. N. Miner
Employment or Leadership Position - Ardea Biosciences
Stock Ownership - Ardea Biosciences
Z. Shen
Employment or Leadership Position - Ardea Biosciences
Stock Ownership - Ardea Biosciences
L. Yeh
Employment or Leadership Position - Ardea Biosciences
Stock Ownership - Ardea Biosciences
R. L. Dubowy
Employment or Leadership Position - Bayer
Stock Ownership - Bayer
M. Jeffers
Employment or Leadership Position - Bayer
P. Rajagopalan
Employment or Leadership Position - Bayer
C. D. Weekes
Honoraria - Ardea Biosciences
Research Funding - Ardea Biosciences